In This Section      
 

Ciccarone Articles

Ciccarone Center Research

Topic

Nutrition, Vitamins, Supplements

Vitamin D in atherosclerosis, vascular disease, and endothelial function.
By: Brewer LC, Michos ED, Reis JP.
Vitamin D deficiency has been linked to an increased risk of hypertension, diabetes, congestive heart failure, peripheral arterial disease, MI, CVA, and related mortality, even after adjustment for traditional cardiovascular risk factors. Accumulating evidence from experimental, clinical, and epidemiological studies suggests that vitamin D may also be associated with several indices of vascular function, including the development and progression of atherosclerotic cardiovascular disease. These findings may provide at least a partial explanation for several recent epidemiologic studies implicating low vitamin D status in the pathogenesis of cardiovascular disease. However, large-scale, well-conducted, placebo controlled clinical trials testing the efficacy of vitamin D supplementation in delaying, slowing, or reversing the atherosclerotic disease process have not yet been conducted. Until the results of these studies are available, we believe it is premature to recommend vitamin D as a therapeutic option in atherosclerosis.
Read on Pubmed
Association of the vitamin D metabolism gene CYP24A1 with coronary artery calcification.
By: Shen H, Bielak LF, Ferguson JF, Streeten EA, Yerges-Armstrong LM, Liu J, Post W, O’Connell JR, Hixson JE, Kardia SL, Sun YV, Jhun MA, Wang X, Mehta NN, Li M, Koller DL, Hakonarson H, Keating BJ, Rader DJ, Shuldiner AR, Peyser PA, Reilly MP, Mitchell BD.
The vitamin D endocrine system is essential for calcium homeostasis, and low levels of vitamin D metabolites have been associated with CVD risk. We hypothesized that DNA sequence variation in genes regulating vitamin D metabolism and signaling pathways might influence variation in CAC. A common SNP in the CYP24A1 gene was associated with CAC quantity in 3 independent populations. This result suggests a role for vitamin D metabolism in the development of CAC quantity.
Read on Pubmed
Vitamin D in atherosclerosis, vascular disease, and endothelial function
By: Brewer LC, Michos ED, Reis JP
Large-scale, well-conducted, placebo-controlled clinical trials testing the efficacy of vitamin D supplementation in delaying, slowing, or reversing the atherosclerotic disease process have not yet been conducted. Until the results of these studies are available, we believe it is premature to recommend vitamin D as a therapeutic option in atherosclerosis.
Read on Pubmed
Omega-3’s for cardiovascular disease prevention.
By: DeFilippis AP, Blaha MJ, Jacobson T.

--

Read on Pubmed
25-hydroxyvitamin D levels, race, and the progression of kidney disease.
By: Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P.
Low 25-hydroxyvitamin D, or 25(OH)D, levels are associated with development of end stage renal disease (ESRD), even after adjustment for multiple risk factors. Low 25(OH)D levels may account for a substantial proportion of the increased risk for ESRD experienced by black individuals.
Read on Pubmed
Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis.
By: Reis JP, von Mühlen D, Michos ED, Miller ER 3rd, Appel LJ, Araneta MR, Barrett-Connor E.

In subgroup analyses, 1,25(OH)(2)D was inversely associated with internal carotid IMT among those with hypertension. These findings from a population-based cohort of older adults suggest a potential role for vitamin D in the development of subclinical atherosclerosis. Additional research is needed to determine whether vitamin D may influence the progression of atherosclerosis, including the effects of supplementation on the atherosclerotic process.

Read on Pubmed